Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 8/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13577681 | 0.87 | CYP4F2 (0.49) | CYP4F2CYP4A11PPARACNR1CNR2 | |
| SCHEMBL16326512 | 0.78 | KDM4E (0.45) | CNR1CNR2MAP4K4NNMTHSD11B1 | |
| SCHEMBL3584331 | 0.78 | KMT2A (0.51) | CNR1CNR2 | |
| SCHEMBL2826311 | 0.77 | MAP4K4 (0.50) | PPARACNR1CNR2MAP4K4NNMT | |
| SCHEMBL16385775 | 0.70 | KDM1A (0.43) | NNMT | |
| SCHEMBL28504688 | 0.69 | DGAT1 (0.59) | — | |
| SCHEMBL23309376 | 0.69 | PPARA (0.44) | CYP4F2CYP4A11PPARACNR1CNR2 | |
| Hydrochloric Acid SCHEMBL28051232 | 0.69 | KDM1A (0.42) | NNMT | |
| SCHEMBL16417282 | 0.67 | MAPK1 (0.59) | — | |
| SCHEMBL23309380 | 0.67 | PPARA (0.47) | CYP4F2CYP4A11PPARACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629470-B2 | Formation of tetra-substituted enamides and stereoselective reduction thereof | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7595417-B2 | Cyanation of aromatic halides | MERCK & CO., INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090018340-A1 | Formation of Tetra-Substituted Enamides and Stereoselective Reduction Thereof | MERCK SHARP & DOHME CORP. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018340-A1 | Formation of Tetra-Substituted Enamides and Stereoselective Reduction Thereof | ENY2, INF2, ECI1 | CYP4F2 455/4885CYP4A11 1917/4885PPARA 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.